Neuralstem (CUR) Misses Q4 EPS by 1c

Neuralstem (NASDAQ: CUR) reported Q4 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

Cash, cash equivalents and short-term investments on hand was approximately $7.6 million at March 31, 2015, compared to approximately $12.2 million at December 31, 2015. The decrease was primarily due to our ongoing operating expenses primarily related to preparations for the initiation of our NSI-189 Phase 2 clinical trial for the treatment of MDD.

For earnings history and earnings-related data on Neuralstem (CUR) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79